Traders sold shares of Biogen Inc. (NASDAQ:BIIB) on strength during trading hours on Thursday. $386.70 million flowed into the stock on the tick-up and $442.51 million flowed out of the stock on the tick-down, for a money net flow of $55.81 million out of the stock. Of all equities tracked, Biogen had the 0th highest net out-flow for the day. Biogen traded up $20.04 for the day and closed at $282.45

Several research analysts have issued reports on BIIB shares. Leerink Swann reissued a “market perform” rating and issued a $328.00 target price (down from $335.00) on shares of Biogen in a research report on Monday, March 28th. BMO Capital Markets started coverage on Biogen in a research report on Tuesday, April 5th. They issued a “market perform” rating and a $283.00 target price on the stock. Jefferies Group dropped their target price on Biogen to $325.00 and set a “buy” rating on the stock in a research report on Wednesday, April 6th. Morgan Stanley dropped their target price on Biogen from $419.00 to $404.00 in a research report on Friday, April 8th. Finally, Citigroup Inc. reissued a “buy” rating and issued a $345.00 target price on shares of Biogen in a research report on Monday, April 11th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and sixteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $321.51.

The stock’s 50-day moving average price is $250.08 and its 200-day moving average price is $262.90. The firm has a market capitalization of $63.04 billion and a P/E ratio of 17.69.

Biogen (NASDAQ:BIIB) last posted its earnings results on Thursday, July 21st. The biotechnology company reported $5.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.69 by $0.52. The business had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.79 billion. During the same period last year, the business earned $4.22 EPS. Biogen’s revenue was up 11.7% compared to the same quarter last year. On average, equities analysts expect that Biogen Inc. will post $19.62 earnings per share for the current year.

In other news, CEO George A. Scangos sold 3,855 shares of Biogen stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $289.74, for a total value of $1,116,947.70. Following the completion of the sale, the chief executive officer now directly owns 56,265 shares of the company’s stock, valued at $16,302,221.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO George A. Scangos sold 157 shares of Biogen stock in a transaction on Wednesday, May 25th. The shares were sold at an average price of $280.00, for a total value of $43,960.00. Following the completion of the sale, the chief executive officer now directly owns 59,633 shares of the company’s stock, valued at $16,697,240. The disclosure for this sale can be found here.

Several large investors have recently modified their holdings of the stock. RidgeWorth Capital Management LLC boosted its stake in shares of Biogen by 0.3% in the fourth quarter. RidgeWorth Capital Management LLC now owns 62,278 shares of the biotechnology company’s stock worth $19,079,000 after buying an additional 184 shares during the last quarter. Madison Investment Holdings Inc. boosted its stake in shares of Biogen by 28.9% in the fourth quarter. Madison Investment Holdings Inc. now owns 58,460 shares of the biotechnology company’s stock worth $17,909,000 after buying an additional 13,100 shares during the last quarter. Afam Capital Inc. purchased a new stake in shares of Biogen during the fourth quarter worth $5,327,000. Liberty Mutual Group Asset Management Inc. boosted its stake in shares of Biogen by 34.6% in the fourth quarter. Liberty Mutual Group Asset Management Inc. now owns 13,593 shares of the biotechnology company’s stock worth $4,164,000 after buying an additional 3,496 shares during the last quarter. Finally, Pinnacle Associates Ltd. boosted its stake in shares of Biogen by 4.2% in the fourth quarter. Pinnacle Associates Ltd. now owns 11,901 shares of the biotechnology company’s stock worth $3,646,000 after buying an additional 479 shares during the last quarter.

Biogen Inc, formerly Biogen Idec Inc, is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.